Collegium Pharmaceutical (NASDAQ: COLL) issues 2026 revenue and adjusted EBITDA outlook

Rhea-AI Filing Summary

Collegium Pharmaceutical, Inc. reported that it has issued full-year 2026 guidance for revenue and adjusted EBITDA. The company disclosed this information in a press release that is furnished as an exhibit and not filed for liability purposes. It also posted a corporate presentation on its website that may be used in discussions with investors, analysts and other stakeholders, and furnished that presentation as a separate exhibit.

The company emphasized that these outlook figures and related commentary are forward-looking statements based on current management expectations and are subject to numerous risks and uncertainties. It highlighted factors such as commercialization performance of its products, market size and acceptance, reimbursement, regulatory developments, litigation, supply, financing needs and intellectual property protection as key risks that could cause actual results to differ materially from the guidance.

Insights

Equity research analyst

Collegium shares 2026 guidance and investor presentation with risk caveats.

Collegium Pharmaceutical, Inc. furnished a press release outlining full-year 2026 revenue and adjusted EBITDA guidance, along with an investor presentation. Because these materials are furnished under Item 7.01 rather than filed, they are positioned as supplemental information for investors rather than forming part of the company’s formal financial statements.

The disclosure underscores that the guidance and related commentary are forward-looking, with management expectations dependent on product commercialization, market conditions, reimbursement, regulatory status and competitive dynamics. It also cites operational factors such as securing active pharmaceutical ingredients, managing customer concentration and complying with U.S. and foreign regulations as potential sources of variability in outcomes.

For investors, the key use of this update is to understand management’s high-level outlook for 2026 and the assumptions behind it, recognizing that numerous enumerated risks could drive actual results away from those expectations. Subsequent 10-K and 10-Q filings are referenced as primary sources for detailed risk factor discussions.

false 0001267565 0001267565 2026-01-08 2026-01-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 8, 2026

COLLEGIUM PHARMACEUTICAL, INC.

(Exact Name of Registrant as Specified in its Charter)

Virginia		001-37372		03-0416362
(State or Other Jurisdiction of Incorporation or Organization)		(Commission File Number)		(IRS Employer Identification No.)

100 Technology Center Drive

Suite 300

Stoughton, MA 02072

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (781) 713-3699

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.001 per share	COLL	The NASDAQ Global Select Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

Item 7.01 Regulation FD Disclosure.

On January 8, 2026, Collegium Pharmaceutical, Inc. (the “Company”) issued a press release announcing full-year revenue and adjusted EBITDA guidance for 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is being furnished, not filed, under Item 7.01 of this Current Report on Form 8-K.

In addition, on January 8, 2026, the Company posted a corporate presentation to its website that representatives of the Company may use from time to time in presentations or discussions with investors, analysts or other parties. A copy of the presentation is attached hereto as Exhibit 99.2 and is being furnished, not filed, under Item 7.01 of this Current Report on Form 8-K.

To the extent that the information in this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 furnished herewith, are not descriptions of historical facts regarding the Company, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as “predicts,” “forecasts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples of forward-looking statements contained in this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 furnished herewith, include, among others, statements related to the Company’s full-year 2026 financial guidance, including projected product revenue, adjusted operating expenses and adjusted EBITDA, current and future market opportunities for its products and the Company’s assumptions related thereto, expectations (financial or otherwise) and intentions, and other statements that are not historical facts. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results, performance, or achievements to differ materially from the Company's current expectations. Actual results may differ materially from management’s expectations and such forward-looking statements in this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 furnished herewith, could be affected as a result of various important factors, including risks relating to, among others: unknown liabilities; risks related to future opportunities and plans for the Company’s products, including uncertainty of the expected financial performance of such products; unknown liabilities; the Company’s ability to commercialize and grow sales of its products; the Company’s ability to manage its relationships with licensors; the success of competing products that are or become available; the Company’s ability to maintain regulatory approval of its products, and any related restrictions, limitations, and/or warnings in the label of an approved product; the size of the markets for the Company’s products, and the Company’s ability to service those markets; the Company’s ability to obtain reimbursement and third-party payor contracts for its products; the rate and degree of market acceptance of the Company’s products; the costs of commercialization activities, including marketing, sales and distribution; changing market conditions for the Company’s products; the outcome of any patent infringement or other litigation that may be brought by or against the Company; the outcome of any governmental investigation related to the Company’s business; the Company’s ability to secure adequate supplies of active pharmaceutical ingredient for each of its products and manufacture adequate supplies of commercially saleable inventory; the Company’s ability to obtain funding for its operations and business development; regulatory developments in the U.S.; the Company’s expectations regarding its ability to obtain and maintain sufficient intellectual property protection for its products; the Company’s ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including U.S. Drug Enforcement Agency compliance; the Company’s customer concentration; and the accuracy of the Company’s estimates regarding expenses, revenue, capital requirements and need for additional financing. These and other risks are described under the heading "Risk Factors" in the Company’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Committee. Any forward-looking statements that the Company makes in this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 furnished herewith, speak only as of the date of this Current Report on Form 8-K. The Company assumes no obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, after the date of this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated January 8, 2026.
99.2		Investor Presentation, dated January 8, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 8, 2026	Collegium Pharmaceutical, Inc.
	By:	/s/ Colleen Tupper
		Name: Colleen Tupper
		Title: Executive Vice President and Chief Financial Officer

FAQ

What did Collegium Pharmaceutical (COLL) disclose in this 8-K?

Collegium Pharmaceutical, Inc. disclosed that it issued full-year 2026 revenue and adjusted EBITDA guidance in a press release and furnished that release and a related investor presentation as exhibits.

Where can investors find Collegium Pharmaceutical's 2026 guidance details?

Investors can find the full-year 2026 revenue and adjusted EBITDA guidance in the press release furnished as Exhibit 99.1, and additional context in the investor presentation furnished as Exhibit 99.2.

Are Collegium Pharmaceutical's 2026 guidance statements considered forward-looking?

Yes. The company states that the 2026 financial guidance and related commentary are forward-looking statements made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

What main risks could affect Collegium Pharmaceutical's 2026 results?

The company highlights risks related to product commercialization, relationships with licensors, market size and acceptance, reimbursement, regulatory approvals and compliance, litigation outcomes, supply of active pharmaceutical ingredients, funding needs, and intellectual property protection.

How are the Collegium Pharmaceutical exhibits in this 8-K treated legally?

The press release (Exhibit 99.1) and investor presentation (Exhibit 99.2) are being furnished, not filed, under Item 7.01, which limits their status for certain liability purposes under the federal securities laws.

Where can investors find more information on Collegium Pharmaceutical's risk factors?

The company directs readers to the "Risk Factors" sections in its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission.